Fluorescence in situ hybridization: powerful molecular tool for cancer prognosis.
We review several aspects of fluorescence in situ hybridization (FISH) technology that demonstrate its breadth and power in detecting and monitoring genetic abnormalities associated with cancers. The clinical utility of FISH in disease management is demonstrated in several examples, including trisomy 8 detection with high specificity and sensitivity in patients with myeloid leukemias; trisomy 12 detection with higher efficiency than conventional cytogenetics in patients with chronic lymphocytic leukemia; assessment of engraftment success, chimerism, and relapse in opposite sex bone marrow transplantation; and correlation of trisomy 7 with survival time in patients with prostate tumors. Advances in FISH technology include multicolor analyses, which permit the simultaneous detection of several genetic abnormalities by using cohybridization of probes labeled with several fluorescent labels or label combinations, and comparative genomic hybridization, a relatively new method whereby a single hybridization can reveal aberrations across the entire genome.
Fox
J L
JL
Hsu
P H
PH
Legator
M S
MS
Morrison
L E
LE
Seelig
S A
SA
D002869:Chromosome Aberrations; D006801:Humans; D017404:In Situ Hybridization, Fluorescence / Q000379:methods; D007938:Leukemia / Q000235:genetics; D009369:Neoplasms / Q000235:genetics*; D011379:Prognosis; D014314:Trisomy